Resultados globales: 1 registros encontrados en 0.02 segundos.
Artículos, Encontrados 1 registros
Artículos Encontrados 1 registros  
1.
6 p, 180.0 KB Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas / Ramanathan, R. K. (Mayo Clinic (USA)) ; Goldstein, D. (Prince of Wales Hospital (Australia)) ; Korn, R. L. (Scottsdale Medical Imaging, Ltd (USA)) ; Arena, F. (NYU Langone Arena Oncology (USA)) ; Moore, M. (Provencial Health Services Authority. BC Cancer Agency (Canada)) ; Siena, S. (Università degli Studi di Millano. Niguarda Cancer Center (Italy)) ; Teixeira, L. (Hôpital Saint-Antoine (France)) ; Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Van Laethem, J.-L. (University Clinic of Brussels. Hôpital Erasme (Belgium)) ; Liu, H. (Biostatistics and Research and Design. Celgene Corporation (USA)) ; McGovern, D. (Biostatistics and Research and Design. Celgene Corporation (USA)) ; Lu, B. (Biostatistics and Research and Design. Celgene Corporation (USA)) ; Von Hoff, D. D. (Translational Genomics Research Institute and Honor Health (USA)) ; Universitat Autònoma de Barcelona
In a phase III pancreatic cancer study, tumor response by positron emission tomography (PET) (exploratory end point) predicted treatment efficacy, including longer overall survival. nab -Paclitaxel/gemcitabine had a significantly higher rate of metabolic response versus gemcitabine. [...]
2016 - 10.1093/annonc/mdw020
Annals of Oncology, Vol. 27, Issue 4 (April 2016) , p. 648-653  

Vea también: autores con nombres similares
1 Korn, R. L.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.